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ABSTRACT 
BACKGROUND.  All studies of treatment free remission (TFR) in chronic myeloid leukaemia 
have discontinued treatment abruptly, and have focussed on stable MR4 (BCR-ABL/ABL ratio 
<0.01%). Information is lacking on more gradual treatment withdrawal and whether TFR is 
feasible for less deep though stable remission. 
METHODS.  The De-Escalation and Stopping Treatment with Imatinib, Nilotinib or sprYcel 
(DESTINY) study (NCT 01804985) recruited 174 adult first chronic phase patients, with all 
(≥3) BCR-ABL qPCR transcript levels < 0.1% (major molecular response; MMR) in the 12 
months before entry. If all were also <0.01%, the patient was assigned to an ‘MR4 group’ (as 
in other studies); patients with result(s) between 0.1% and 0.01% were allocated to a novel 
‘MMR group’. Treatment was de-escalated to half the standard dose for 12 months, then 
stopped for a further 24 months, with frequent PCR monitoring. Recurrence was defined as 
the first of 2 consecutive samples >0.1%; this required treatment recommencement at full 
dose. 
FINDINGS.  Treatment at entry was imatinib (148), nilotinib (16) or dasatinib (10), for a median 
of 6.9 years. Recurrence free survival after 36 months on study (the primary endpoint), was 
72% (95% CI: 64-80%) in MR4 patients, and 36% (95% CI 25-53%) in the MMR group. 
Treatment duration predicted recurrence (p=0.021), but age, gender or performance status 
did not. Patient diaries revealed improvement of common treatment related symptoms both 
on initial de-escalation and again on stopping. No disease progression was seen; two deaths 
occurred due to unrelated causes. All recurrences regained MMR within 5 months of treatment 
resumption. 
INTERPRETATION.  Initial de-escalation may improve the success of TFR, though the 
mechanism of its benefit is not yet clear. Both de-escalation and stopping treatment improve 
symptoms. The findings also suggest that TFR merits further study in stable MMR patients.  
FUNDING.  Newcastle University and Bloodwise. 
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INTRODUCTION 
Thanks to tyrosine kinase inhibitors (TKIs), the life expectancy of the vast majority of patients 
who are newly diagnosed with chronic myeloid leukaemia is now comparable to healthy age-
matched individuals1. This dramatic improvement in outlook is mainly due to the efficacy of 
TKI therapy, aided by highly efficient molecular monitoring which can detect BCR-ABL1 
transcripts at very low levels. This has led to increasing focus on the side effects of therapy2 
and on whether after a few years of TKI therapy it may be possible to stop treatment.  
 
Begun in 2006, the STIM study of stopping imatinib in 100 French patients in deep remission 
established that treatment free remissions (TFRs) are possible for some patients3. Several 
subsequent TFR studies (reviewed in 4 and 5) have used the loss of major molecular 
response (MMR, defined as a BCR-ABL1 to ABL1 transcript ratio of <0.1%) as the definition 
of molecular recurrence. The largest of these is the EUROSKI trial, which recently reported a 
molecular recurrence-free survival (RFS) of 61% at 6 months and 50% at 24 months after 
treatment cessation6 in 755 evaluable patients. This study also found that longer treatment 
duration and longer deep molecular response durations were associated with increased 
probability of maintenance of MMR 6 months after treatment cessation. 
 
The vast majority of TFR studies so far have abruptly stopped TKI therapy in patients 
consistently in MR4 (BCR-ABL1 to ABL1 transcript ratio of < 0.01%). It is possible that some 
patients who would have experienced molecular recurrence with this approach might 
maintain MMR on lower than standard TKI doses, relieving ongoing TKI-related side effects. 
Reduction of therapy in 19 patients in established deep remissions appears safe7, and 
recent mathematical modelling data suggest that this may not lead to a reduction of long-
term treatment efficacy for most patients8. In addition, apart from anecdotal reports9,10 and a 
study of 12 patients11 TFR has not been formally studied in patients achieving enduring 
MMR but not necessarily MR4. The present study was designed to examine these TFR 
questions. Entry was permitted for patients with stable MMR over the previous 12 months, 
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and patients were stratified into either an MR4 (or deeper) group as in many other studies, or 
a novel MMR group not previously studied. The trial design comprised initial de-escalation to 
half the standard TKI dose for 12 months, followed by complete cessation. 
 
Interim results of the de-escalation phase of this De-Escalation and Stopping Treatment with 
Imatinib, Nilotinib or sprYcel (DESTINY) study have been published12. We now present the 
final results of the study after the subsequent 24 months of treatment cessation. 
 
METHODS 
Study design and participants 
The trial was part of the UK National Cancer Research Institute portfolio, and was registered 
at https://clinicaltrials.gov/ as NCT 01804985. It was sponsored jointly by the University of 
Liverpool and the Royal Liverpool and Broadgreen University Hospitals Trust, and was 
approved by the North West - Liverpool East Committee of the UK National Research Ethics 
Service. Trial entry required fulfilment of all the following: aged ≥18; in first chronic phase 
with a known BCR-ABL1 transcript (any transcript type was permitted); ≥3 years of therapy 
with either imatinib, nilotinib or dasatinib; no change in TKI unless for intolerance (once 
only); ≥3 PCR measurements over the preceding 12 months, each with ≥10,000 ABL1 
control transcripts AND BCR-ABL/ABL1 ratio of ≤ 0.1%. If all PCR measurements during this 
pre-trial observation period were ≤ 0.01% (i.e. in MR4 throughout), the patient was assigned 
to an ‘MR4 group’; if some or all were > 0.01% but ≤ 0.1%, the patient was assigned to an 
‘MMR group’. Prior interferon-α therapy was permitted if discontinued ≥12 months before 
entry. Recipients of ponatinib or bosutinib or of doses higher than imatinib 400mg daily, 
nilotinib 400mg twice daily or dasatinib 100mg daily (unless within a trial comparing front-line 
standard and higher doses) were all excluded. 
 
Procedures 
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The treatment strategy was identical for both groups, and comprised 2 sequential phases; an 
initial 12 months of de-escalation to half the standard TKI dose at the time of trial design, 
followed by 24 months of treatment cessation. The dose during de-escalation comprised 
continuing the same TKI at imatinib 200mg daily, nilotinib 200mg twice daily, or dasatinib 
50mg daily. Patients already on reduced doses of TKI because of intolerance of the standard 
dose were eligible as long as their dose was at least the de-escalation dose. Molecular 
monitoring was carried out centrally at Imperial College Molecular Pathology at 
Hammersmith Hospital, London, monthly for the first 2 years and alternate months 
thereafter. PCR results for the 172 patients with e13a2 and/or e14a2 transcripts were 
expressed using International Scale (IS) standardisation (the remaining 2 patients had the 
e19a2 transcript). 
 
Outcomes 
The primary end-point for both the MR4 and the MMR groups was the proportion of patients 
who can first de-escalate their treatment (to half the standard dose of their TKI) for 12 
months, and then stop treatment completely for a further 2 years, without losing MMR. This 
was estimated separately for the MR4 and MMR groups. Molecular recurrence, defined as 
loss of MMR, was timed as the first of two consecutive results > 0.1%. Such patients were 
required to resume their entry TKI at the full standard dose, and were followed monthly until 
the PCR was ≤ 0.1%IS, at which point they were taken off trial.  
Secondary endpoints comprised the following, all of which are summarised in 
Supplementary Table 2 in the WebAppendix: overall survival (OS, the time from 
commencing de-escalation to death from any cause); progression-free survival (PFS, the 
time from commencing de-escalation to the earlier of date of progression to advanced phase 
or death from any cause); event-free survival (EFS, the time from commencing de-escalation 
to the date of confirmed loss of MMR, progression to advanced phase or death from any 
cause); the proportion of patients who lose MMR on de-escalation/stopping and regain MMR 
on resumption of their TKI, and their time to MMR recovery (TTR, defined as the time from 
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the date of confirmed loss of MMR to the date of MMR recovery); the proportion of patients 
who successfully de-escalate treatment but then lose MMR on complete TKI cessation; the 
proportion of patients in confirmed MR4.5 (BCR-ABL ≤ 0.0032% IS with at least 31,623 
ABL1 control transcripts) prior to being enrolled in the study. The following secondary 
endpoints have already been reported: Health Economic Assessment12, Quality of Life12 and 
laboratory studies to identify subsets of patients who are more likely to relapse on de-
escalation / cessation18.   
Patients were asked to keep a diary throughout their follow-up, recording any new symptoms 
and the evolution of already reported ones, and to grade these according to the standard 
National Cancer Institute Common Toxicity Criteria. The diaries were semistructured, 
specifically asking about the symptoms presented in the WebAppendix). FACT-BRM and 
EQ-5D Quality of Life data at trial entry were already comparable to a healthy control 
population as previously reported12, suggesting that these instruments are too insensitive for 
well controlled chronic myeloid leukaemia. 
 
 
Statistical analysis 
The sample size was calculated assuming a worst-case scenario (proportion of relapsing 
patients = 0.5; group allocation of 1:3 in either direction; 17% dropouts ), and estimated that 
168 patients would provide 90% confidence intervals (CI) with maximum width of 0.16 and 
0.28 for the “larger” and “smaller” group respectively. 
Although no formal stopping rules were defined, three pre-planned Interim Analyses were 
performed and reviewed by an Independent Safety Data Monitoring Committee, to allow early 
termination of either group if an unacceptable RFS was observed. 
All statistical analyses were performed on an intention-to-treat basis using R (version 3.3.1). 
No adjustment for multiple testing or missing data was incorporated. Continuous variables 
were summarised using median and inter quartile range (IQR) values, whereas frequencies, 
proportions and polar charts were used for categorical variables. The RFS was estimated 
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using the Kaplan Meier method and reported with 95% CI. For the estimation of time to MMR 
recovery, cumulative incidence analysis adjusting for the competing risk of death/progression 
to advanced phase was used. Univariate and multivariate Cox regression analysis were used 
to explore the effect of various trial entry characteristics on RFS.  
 
Role of the funding source 
The sponsor and the funding sources had no role in study design, or collection, analysis, or 
interpretation of the data or in the writing of this manuscript. Authors REC (corresponding 
author), FP and LR had full access to all of the data, and LF had access to the molecular 
data. Authors REC and FP had the final responsibility to submit for publication. 
 
 
RESULTS 
The trial recruited at 20 British centres listed on page 1 of the WebAppendix, between 16th 
December 2013 and 6th May 2015. A total of 335 patients were screened, but 161 did not 
enter the trial. These comprised 67 patients who declined due to concern over additional 
visits (19) or bone marrow aspiration (requested at entry and recurrence for laboratory 
research studies (4)), apprehension about stopping treatment (7), or no information available 
(37), and 94 who were ineligible (didn’t meet all the inclusion criteria (29), exceeded ≥1 
exclusion criterion (40), or study closed to recruitment before the patient was registered 
(25)). 
Clinical details of the 174 entrants have been previously published12 and are summarised 
here as Supplementary Table 1 on page 2 of the WebAppendix for completeness. At entry, 
148 patients were receiving imatinib, 16 nilotinib and 10 dasatinib, for a median duration of 
6.9 years (IQR 4.8 – 10.2 years). The CONSORT diagram in Figure 1 gives their flow 
through the trial; the MR4 and MMR groups comprised 125 and 49 patients respectively. All 
but 2 entrants had either an e13a2 or an e14a2 BCR-ABL1 transcript; the remaining 2 had 
an e19a2. Three (2%) MR4 and 9 (18%) MMR patients relapsed during the de-escalation 
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phase, as previously reported12, and 4 and 1 patients respectively from these groups 
withdrew consent before completion of de-escalation from concern regarding stopping 
treatment; thus 118 MR4 and 39 MMR patients entered the treatment cessation phase. 
 
Molecular recurrence  
Figure 2 gives the RFS for each group. In the MR4 group, 84 of the original 125 entrants 
reached the 36 month trial completion point, giving a 3-year RFS of 72% (95% CI 64-80%). 
Recurrence was seen in 34 patients, and 7 discontinued for other reasons (5 withdrew 
consent, 1 pregnancy, 1 protocol violation). In the MMR group, 16 of the 49 entrants 
completed the study, giving a 3-year RFS of 36% (95% CI 25-53%) with 30 molecular 
recurrences and 3 consent withdrawals. The RFS is significantly worse in the MMR group 
than in the MR4 group (log rank statistic 27.11; p < 0.001). Outcomes of the secondary 
endpoints are given in Supplementary Table 2 on page 3 of the Appendix. 
 
In exploratory analysis, of the 4 scoring systems using diagnostic data to predict long term 
outcome in chronic myeloid leukaemia 13-16, Supplementary Table 3 on page 4 of the 
Appendix summarises the comparison of high vs low/intermediate scores for the 74 patients 
with available data. No significant association was seen between any of these scores and 
the RFS, nor if high/intermediate scores were compared with low scores. Similarly, no 
significant association was seen when the MMR or MR4 groups were considered in isolation 
(data not shown). 
 
Allocation to the MMR group 
Per protocol, patients were allocated to the MMR or MR4 group according to the pattern of 
PCR results in the pre-entry 12 month observation period. A sensitivity analysis was carried 
out to see how this differed from merely allocating patients to MR4 or MMR groups by their 
single centralised molecular result at trial entry. Of the 125 patients that were classified as 
MR4 based on local results, 124 (99%) were ‘confirmed’ as MR4 by the centralised 
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molecular assessment. However, this single entry result would have allocated 38 of the 49 
MMR patients to the MR4 group, and 15 of these (39%) completed the study without 
recurrence. Of the 11 MMR patients who would remain in an MMR group if categorised on a 
single entry molecular assessment, 3 completed the study without recurrence (RFS 31%), all 
of whom achieved MR4 during the de-escalation phase. These RFS results for these 
different subpopulations within the protocol-defined MMR group therefore appear similar, 
and consistent with the overall results for the MMR group, though this clearly requires further 
study.  
 
Molecular recurrence in patients in MR4.5 on study entry 
Figure 3 shows the RFS stratified according to whether in MR4.5 (defined at BCR-
ABL1:ABL1 ≤ 0.0032%IS) or not at trial entry. In the MR4 group, for patients with at least 
31623 control transcripts, being in MR4.5 at study entry confers no advantage (p=0.99). In 
the MMR group (where a patient can also be in MR4.5 at trial entry, since the assignment to 
trial group was determined by the previous 12 months local PCR results, whereas the 
assessment of molecular status was by central molecular analysis at trial entry), being in 
MR4.5 also confers no advantage (p=0.47), though the numbers at risk of recurrence 
become very low beyond ~18 months. 
 
Molecular recurrence in patients on less than standard TKI doses on entry 
Twenty-six patients entered the trial on TKI doses lower than standard. These comprised 
imatinib at an average once daily dose of 300mg (13), 200mg (3), 350 or 250 mg (1 each), 
nilotinib at twice daily doses of 300mg (4), 225 or 200mg (1 each), or dasatinib at a once 
daily dose of 80 or 50mg (1 each); their distribution by group and individual outcome has 
been previously reported (Table 4 of reference 12). The exclusion of these 26 “less than 
standard dose” entrants does not affect the RFS at 36 months: in the MR4 group this 
becomes 68% (from 72%) and in the MMR group 37% (from 36%). 
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Predictive factors for molecular recurrence 
The results of Cox regression analysis of the association between various trial entry 
characteristics and the RFS are shown in Table 1. It was not feasible to include Time in 
MR4, since this is only applicable for the MR4 patients, in whom there are few recurrence 
events. Furthermore, both Time in MR4 and Time in MMR were incomplete, since complete 
molecular data from original diagnosis were unavailable for 80 patients, and were invariably 
locally derived and not to IS. Conversely, Time on TKI was easily retrieved from the 
treatment history. 
In univariate analysis, no relationship was seen with the length of time in MMR before trial 
entry, but there was a significant association between trial group and recurrence, as 
expected from Figure 2. Being in MR4.5 at trial entry was also strongly correlated with 
continued molecular remission, since most MR4.5 patients were in the MR4 group. There 
was also a trend for fewer recurrences in patients with longer treatment durations; although 
the proportion of recurrences in the shortest two quartiles (3-5 and 5-7 years on TKI) is 
comparable (46% and 55% respectively), this drops to 28% and 24% for the longest two 
quartiles (7-10 and 10-14 years on TKI respectively). However, this distribution differs for the 
two trial groups, in that the proportion of recurrences falls below 50% beyond 7 years of TKI 
therapy in the MR4 group, but not until after 9 years of therapy in the MMR group (data not 
shown), suggesting that MMR patients may need around 2 extra years of TKI therapy to 
achieve similar RFS to MR4 patients. 
In multivariate analysis, the only significant factors predictive of recurrence were the trial 
group and the duration of TKI treatment. Using the backward elimination method with a p 
value = 0.1 as threshold, the selected final model was: 
 
ln (λ(t)/ λ0(t)) = -1.309 x [Molecular Group = MR4] – 0.083 x Time on TKI (in years) 
  
where being in the MR4 group = 1 and the expression  ln (λt/ λ0(t)) represents the log 
hazard ratio that the Cox Proportional Hazards model is estimating. This model estimates a 
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non-linear average decrease in the proportion of recurrences of ~8% per additional year on 
TKI in the trial overall (reflected by the hazard ratio of 0.92 in Table 1), but again this differs 
according to trial group with an average 4% decreased recurrence rate/year for the MR4 
group and 11% for the MMR group. 
 
Recovery from molecular recurrence 
Patients with recurrences were required to resume the full dose of their entry TKI, and all 
complied with this. Figure 4 gives the recovery from molecular recurrence classified 
according to our protocol definition. Of the 64 recurrences across the trial, 58 returned to 
MMR within 5 months of TKI resumption, with no significant difference (p=0.59) between the 
MR4 and MMR arms. Six patients (3 in each trial group) opted to either delay TKI 
resumption or to resume at less than full dose. This protocol violation precluded formal 
central molecular monitoring; however local PCR data in all 6 cases documented their return 
to MMR within 5 months. 
 
Adverse events 
During follow-up, two patients died due to worsening of pre-existing chronic obstructive 
pulmonary disease or peripheral arterial occlusive disease (both patients had only ever 
received imatinib). No patient underwent disease progression. One patient lost 
haematological response at the time of recurrence, this was rapidly regained on TKI 
resumption. 
 
A total of 27 serious adverse events in 17 patients were reported, as given in Table 2. These 
include 4 myocardial infarctions and 1 episode of complete atrioventricular block, and 7 
infections. All were declared as unrelated to the trial or the underlying disease. Non-serious 
adverse events were not recorded in this trial. 
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Using data from patient diaries, Supplementary Figure 1 on page 5 of the WebAppendix 
gives the frequency of individual TKI associated side effects over time. In each group, all 
improve especially in the first 3 months after both de-escalation and also stopping, though 
not thereafter. 
 
During the first 12 months of the stopping phase, 56 (40%) of 141 assessible patients 
reported musculoskeletal symptoms comprising arthralgia (38), either generalised (21) or of 
specific joints or combinations thereof (17), myalgia (10), either generalised (6) or at various 
sites (1) or as muscle cramps (3) or both (5) or bone pain (3). The trial was however not 
designed to collect detailed information on the duration,or treatment of these symptoms. 
 
DISCUSSION 
There has been considerable interest in TFR in chronic myeloid leukaemia in the recent 
past4,5, with most studies typically showing RFS (defined as loss of MMR) of 50-60% in first 
chronic phase patients on TKI for some years and in stable MR4. Here we extend 
knowledge about TFR in two important ways. 
 
Firstly, in patients in stable MR4, prefacing treatment cessation by a year of de-escalation 
produces an excellent subsequent 2 year RFS of 72%, which has only been equaled by a 
small study of interferon maintenance on imatinib withdrawal17. Though not a randomised 
comparison with abrupt cessation, the present result appears superior to all other TFR 
studies of TKI treatment withdrawal in chronic myeloid leukaemia, notably the recently 
published large EUROSKI study, which reported a 2-year RFS of 50% 6. Our entry criteria 
for MR4 patients were deliberately almost identical to EUROSKI, differing only in that we did 
not mandate an e13a2 or e14a2 transcript (2 patients expressed an e19a2 transcript, one of 
whom had a recurrence) or inclusion of diagnostic components of the Sokal score. Other 
TFR studies have used a single PCR value > 0.1% to define molecular recurrence, whereas 
here recurrence is defined as the first of 2 consecutive values > 0.1%. Altering our 
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recurrence definition to a single result > 0.1% brings forward the timing of recurrence in 8 
cases (5 MR4, 3 MMR) but has a negligible effect on the RFS (68% (from 72%) in the MR4 
group and 30% (from 36%) in the MMR group). 
 
The median durations of therapy in the present MR4 group and the comparable EUROSKI 
study patients differ by a year (6.5 vs. 7.5 years respectively), though the initial year of de-
escalation in DESTINY may somewhat mitigate this difference. However, the mean benefit 
of additional treatment on RFS for the MR4 group is 4% per additional year, which as stated 
is comparable to the 3% observed in the EUROSKI study. It is therefore likely that the year 
of de-escalation has some bearing on the present excellent result for the MR4 group. 
Possible mechanisms might include altering the quiescent proportion of leukaemic stem cells 
(LSC) at a time when TKI is still present, or altering competition for the haematopoietic niche 
in favour of normal haematopoietic stem cells, but investigation of this is difficult as by 
definition there are very few LSC available for study. Alternatively, TKI de-escalation may 
modify anti-leukaemic immune responses. We have recently shown that changes in CD4+ 
regulatory T cells, CD56dim and CD56bright NK cell subsets occur during TKI de-escalation; 
indeed no further changes are seen on stopping for any subset; furthermore a rise in the 
effector memory CD8+ subset predicts molecular recurrence18. Treatment discontinuation is 
more successful in patients with higher NK cell levels 19,20, and less successful with higher 
CD86+ plasmacytoid dendritic cells21. Overall, current data are compatible with the view that 
the effect of TKIs on immune cell subset numbers and function may be greater in patients 
who will relapse after treatment discontinuation. The relative contribution of LSC activation 
and the immune system clearly requires further study, and it will also be interesting to look at 
whether longer periods of de-escalation can mitigate the sharp fall in RFS after subsequent 
cessation. 
 
Secondly, we have included patients in stable MMR but not MR4 in a formal TFR study. 
Their RFS over the entire 36 months of study is 36%. This is a potentially practice-changing 
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result since hitherto TFR attempts in MMR-only patients have been discouraged 5, though 
we stress that further studies are required in this patient group. Their heterogeneous PCR 
patterns during the pre-trial entry observational year range from those with all but one PCR 
result in MR4 to those with several results close to 0.1%. These extremes have similar RFS 
to the whole MMR group, though a larger sample size is required to determine whether 
particular PCR patterns affect the success of TFR. 
Multivariate analysis revealed that the length of time on TKI (though not time in MMR) is 
associated with an improved RFS. We could not examine the effect of time in MR4 on 
recurrence, since our MR4 group had rather few recurrence events. The mean improvement 
in 2 year RFS of 8% per additional year of TKI is not linear with gradations in TKI duration, 
and the mean 4% improvement in RFS per additional treatment year for the MR4 group is 
comparable to the 3% seen in the EUROSKI study of similar patients 6. The greater benefit 
of additional treatment years for the MMR group, together with the tantalising finding that the 
RFS in MMR patients may be similar to MR4 patients after ~2 additional treatment years, 
require confirmation in further studies. 
 
Our study has some limitations. Firstly, the local molecular assessments in the 12 month 
observation period prior to trial entry (i.e. during 2012-14) were not to IS. This arises 
because IS was not in universal use in the UK health service until ~2016, though this was 
similar to many other European countries and it is therefore possible that other 
contemporary and earlier studies may also be guilty of this problem. Furthermore, local and 
centralised results are at different time points, and characterising patients by serial pre-trial 
data may not be the same as defining at a single baseline molecular test. Although we show 
that these two alternatives do not make a difference for the MR4 group, in our novel MMR 
group 38 of the 49 patients would have been classified as in MR4 by their centralised 
baseline result, yet have an RFS that is clearly inferior to patients defined as MR4 by serial 
pre-trial molecular data. This suggests that a single PCR result at trial entry may be less 
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powerful in predicting recurrence than the PCR trend before trial entry as used here. This 
will be an important area to consider in future studies, especially for MMR patients.  
 
A further limitation is that follow up was curtailed at 36 months. Sites were encouraged to 
report patient outcome beyond this time, but this was not mandatory. Although Figure 2 
shows that the number of recurrences in the final year of follow-up is low, in line with other 
studies, longer follow-up would be helpful, especially for the novel MMR group. We have 
previously shown that on de-escalation, the incidence of common TKI-associated symptoms 
typically improves 12, and now show that there is further improvement on subsequently 
discontinuing TKI in both trial groups. These data are derived from patients’ own diaries and 
are therefore not subject to possible bias by trialists as can occur with traditionally reported 
adverse events. It is not possible to examine whether symptom improvement is related to 
RFS, because recurrences are almost all in the first few months of stopping and these 
patients will therefore not have data on symptom changes, a problem known as immortal 
time bias. 
 
In summary, we present data that initial de-escalation may improve the proportion of patients 
in stable MR4 who can successfully undergo a TFR attempt, though the mechanism of its 
benefit is not yet clear. In this regard it would be of considerable interest to carry out a meta-
analysis of the present MR4 patients and those in EUROSKI. Different de-escalation 
strategies, both more gradual and more rapid, will be of considerable interest. We also use 
the same strategy in patients not in stable MR4, here labelled MMR, who have rarely been 
included in TFR studies to date. Approximately one-third of such patients remain in TFR 2 
years after TKI cessation, but caution is urged in stopping treatment in MMR patients outside 
a clinical trial, as further TFR data are urgently required for this group. 
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LEGENDS to TABLES and FIGURES 
 
Table 1. Univariate and multivariable analysis of various parameters’ association 
with molecular recurrence. Where relevant, the hazard ratio refers to the probability 
of recurrence for the named parameter relative to the alternative (e.g. MR4 vs. MMR; 
male vs. female; imatinib vs. other entry drugs). CI = confidence interval. 
 
Table 2. Serious adverse events (SAE). 
 
Figure 1. CONSORT diagram for the trial. 
 
Figure 2: Molecular recurrence-free survival (RFS) for each trial group. CI = 
confidence intervals. 
 
Figure 3: Molecular recurrence stratified according to whether in MR4.5 at trial entry. 
Dotted lines = in MR4.5; solid lines = not in MR4.5. Red lines = MR4 group patients; 
blue lines = MMR group.  
 
Figure 4: Recovery from molecular recurrence per protocol.  
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Table 1.    
Univariate    
CHARACTERISTIC HAZARD RATIO 95% CI p-value 
    
Molecular group MR4 0.29 0.18-0.48 <0.001 
    
Age 0.99 0.97-1.01 0.19 
    
Gender Male 0.70 0.43-1.14 0.15 
    
Medication imatinib 1.60 0.73-3.52 0.23 
    
ECOG score 0.83 0.37-1.83 0.64 
    
Time on TKI 0.94 0.87-0.99 0.082 
    
Time in MMR 0.92 0.83-1.03 0.13 
    
MR4.5 at entry  0.43 0.26-0.72 0.001 
    
    
Multivariable    
CHARACTERISTIC HAZARD RATIO 95% CI p-value 
    
Molecular group MR4 0.27 0.16-0.44 <0.001 
    
Time on TKI 0.92 0.86-0.99 0.021 
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Table 2. 
 
Severity: No. of SAEs (No. of patients) 
CTCAE Category (No. of SAEs) CTCAE short name (No. of SAEs) Group 1 2 3 4 5 
Cardiac disorders (7) Myocardial infarction (4), 
Atrioventricular block complete (1), 
Chest pain – cardiac (1), Syncope (1) 
MMR - - - - - 
MR4 - 3 (2) 4 (4) - - 
Eye disorders (1) Other (1) MMR - - 1 (1) - - 
MR4 - - - - - 
Gastrointestinal disorders (1) Abdominal pain (1) MMR - - - - - 
MR4 - - - 1 (1) - 
General disorders and administration site  
conditions (1) 
Pain (1) MMR - - - - - 
MR4 - - 1 (1) - - 
Hepatobiliary disorders (1) Gallbladder pain (1),  
Other (1) 
MMR - - - - - 
MR4 - - 2 (1) - - 
Immune system disorders (1) Allergic reaction (1) MMR - - - - - 
MR4 - 1 (1) - - - 
Infections and infestations (7) Sepsis (3), Urinary tract infection (2), 
Skin Infection (1), Vaginal infection (1) 
MMR - - 1 (1) - - 
MR4 - 3 (2) 3 (3) - - 
Injury, poisoning, procedural  
Complications (2) 
Other (2) MMR - - - - - 
MR4 - - 2 (1) - - 
Musculoskeletal and connective 
tissue disorders (2) 
Bone pain (1), 
Other (1) 
MMR - - - - - 
MR4 - - 2 (2) - - 
Nervous system disorders (1) Headache (1) MMR - - - - - 
MR4 1 (1) - - - - 
Renal and urinary disorders (1) Urinary retention (1) MMR - - - - - 
MR4 - 1 (1) - - - 
Vascular disorders  (1) Other (1) MMR - - 1 (1) - - 
MR4 - - - - - 
Total 
MMR - - 3 (3) - - 
MR4 1 (1) 8 (6) 14 (12) 1 (1) - 
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Figure 1.  CONSORT diagram 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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